The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors
Open accessAbstract
Synthetic benzamide derivatives were investigated for their ability to inhibit histone deacetylase (HDA). In this study, one of the most active benzamide derivatives, MS-27-275, was examined with regard to its biological properties and antitumor efficacy. MS-27-275 inhibited partially purified human HDA and caused hyperacetylation of nuclear histones in various tumor cell lines. It behaved in a manner similar to other HDA inhibitors, such as sodium butyrate and trichostatin A; MS-27-275 induced p21 WAF1/CIP1 and gelsolin and changed the cell cycle distribution, decrease of S-phase cells, and increase of G 1 -phase cells. The in vitro sensitivity spectrum of MS-27-275 against various human tumor cell lines showed a pattern different than that of a commonly used antitumor agent, 5-fluorouracil, and, of interest, the accumulation of p21 WAF1/CIP1 tended to be faster and greater in the cell lines sensitive to MS-27-275. MS-27-275 administered orally strongly inhibited the growth in seven of eight tumor lines implanted into nude mice, although most of these did not respond to 5-fluorouracil. A structurally analogous compound to MS-27-275 without HDA-inhibiting activity showed neither the biological effects in cell culture nor the in vivo therapeutic efficacy. These results suggest that MS-27-275 acts as an antitumor agent through HDA inhibition and may provide a novel chemotherapeutic strategy for cancers insensitive to traditional antitumor agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
Genetic Alterations during Colorectal-Tumor Development
Vogelstein, B., Fearon, E. R., Hamilton, S. R., Kern, S. E., Preisinger, A. C., Leppert, M., Smits, A. M. M., & Bos, J. L. (1988) · New England Journal of Medicine · doi:10.1056/nejm198809013190901 · Cited by 6,728
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
p21 is a universal inhibitor of cyclin kinases
Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., & Beach, D. (1993) · Nature · doi:10.1038/366701a0 · Cited by 3,368
Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia
Huang, M., Ye, Y., Chen, Sr., Chai, Jr., Lu, J., Zhoa, L., Gu, L., & Wang, Z. (1988) · Blood · doi:10.1182/blood.v72.2.567.567 · Cited by 2,445
Vogelstein, B. (1992) · Cell · doi:10.1016/0092-8674(92)90421-8 · Cited by 1,862
Yoshida, M., Kijima, M., Akita, M., & Beppu, T. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)44885-x · Cited by 1,854
Dulić, V., Kaufmann, W. K., Wilson, S. J., Tisty, T. D., Lees, E., Harper, J. W., Elledge, S. J., & Reed, S. I. (1994) · Cell · doi:10.1016/0092-8674(94)90379-4 · Cited by 1,465
The retinoblastoma protein is phosphorylated during specific phases of the cell cycle
Buchkovich, K., Duffy, L. A., & Harlow, E. (1989) · Cell · doi:10.1016/0092-8674(89)90508-4 · Cited by 995
Chen, P.-L., Scully, P., Shew, J.-Y., Wang, J. Y. J., & Lee, W.-H. (1989) · Cell · doi:10.1016/0092-8674(89)90517-5 · Cited by 952
A direct link between core histone acetylation and transcriptionally active chromatin.
Hebbes, T. R., Thorne, A. W., & Crane-Robinson, C. (1988) · The EMBO Journal · doi:10.1002/j.1460-2075.1988.tb02956.x · Cited by 923
DeCaprio, J. A., Ludlow, J. W., Lynch, D., Furukawa, Y., Griffin, J., Piwnica-Worms, H., Huang, C.-M., & Livingston, D. M. (1989) · Cell · doi:10.1016/0092-8674(89)90507-2 · Cited by 897
O'Connor, P. M., Jackman, J., Bae, I., Myers, T. G., Fan, S., Mutoh, M., Scudiero, D. A., Monks, A., Sausville, E. A., Weinstein, J. N., et al. (1997) · PubMed · Cited by 867
What's Up and Down with Histone Deacetylation and Transcription?
Pazin, M. J., & Kadonaga, J. T. (1997) · Cell · doi:10.1016/s0092-8674(00)80211-1 · Cited by 821
n-Butyrate causes histone modification in HeLa and Friend erythroleukaemia cells
RIGGS, M. G., WHITTAKER, R. G., NEUMANN, J. R., & INGRAM, V. M. (1977) · Nature · doi:10.1038/268462a0 · Cited by 787
Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit
Gu, Y., Turck, C. W., & Morgan, D. O. (1993) · Nature · doi:10.1038/366707a0 · Cited by 764
Kijima, M., Yoshida, M., Sugita, K., Horinouchi, S., & Beppu, T. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)41547-5 · Cited by 514
Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiPl
Somasundaram, K., Zhang, H., Zeng, Y.-X., Houvras, Y., Peng, Y., Zhang, H., Wu, G. S., Licht, J. D., Weber, B. L., & El-Deiry, W. S. (1997) · Nature · doi:10.1038/38291 · Cited by 509
Alternative chromatin structure at CpG islands
Tazi, J. (1990) · Cell · doi:10.1016/0092-8674(90)90339-g · Cited by 481
Histone acetylation: chromatin in action
Wade, P. A., Pruss, D., & Wolffe, A. P. (1997) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(97)01016-5 · Cited by 471
Wolf, D., & Rotter, V (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.3.790 · Cited by 410
Nakano, K., Mizuno, T., Sowa, Y., Orita, T., Yoshino, T., Okuyama, Y., Fujita, T., Ohtani-Fujita, N., Matsukawa, Y., Tokino, T., et al. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.35.22199 · Cited by 395
On the biological role of histone acetylation
Csordas, A. (1990) · Biochemical Journal · doi:10.1042/bj2650023 · Cited by 249
Histone Acetylation and Chromatin Assembly: A Single Escort, Multiple Dances?
Roth, S. Y., & Allis, C. D. (1996) · Cell · doi:10.1016/s0092-8674(00)81316-1 · Cited by 248
Clinical pharmacology of sodium butyrate in patients with acute leukemia
Miller, A. A., Kurschel, E., Osieka, R., & Schmidt, C. G. (1987) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(87)90109-x · Cited by 246
Kim, Y. S., Tsao, D., Siddiqui, B., Whitehead, J. S., Arnstein, P., Bennett, J., & Hicks, J. (1980) · Cancer · doi:10.1002/1097-0142(19800315)45:5+<1185::aid-cncr2820451324>3.0.co;2-w · Cited by 234
Increased accumulation of p53 protein in cisplatin‐resistant ovarian cell lines
Brown, R., Clugston, C., Edlin, A., Vasey, P., Kaye, S. B., Burns, P., & Vojtěšek, B. (1993) · International Journal of Cancer · doi:10.1002/ijc.2910550428 · Cited by 202
Kwon, H. J., Owa, T., Hassig, C. A., Shimada, J., & Schreiber, S. L. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3356 · Cited by 197
Hoshikawa, Y., Kwon, H. J., Yoshida, M., Horinouchi, S., & Beppu, T. (1994) · Experimental Cell Research · doi:10.1006/excr.1994.1248 · Cited by 188
Gelsolin: a candidate for suppressor of human bladder cancer.
Tanaka, M., Müllauer, L., Ogiso, Y., Fujita, H., Moriya, S., Furuuchi, K., Harabayashi, T., Shinohara, N., Koyanagi, T., & Kuzumaki, N. (1995) · PubMed · Cited by 186
Ruggeri, B., Zhang, S.-Y., Caamaño, J., DiRado, M., Flynn, S. D., & Klein–Szanto, A. J. (1992) · PubMed · Cited by 172
Cioé, L., McNab, A. R., Hubbell, H. R., Meo, P., Curtis, P. J., & Rovera, G. (1981) · PubMed · Cited by 167
Allegra, P., Sterner, R., Clayton, D. F., & Allfrey, V. G. (1987) · Journal of Molecular Biology · doi:10.1016/0022-2836(87)90698-x · Cited by 163
Novogrodsky, A., Dvir, A., Ravid, A., Shkolnik, T., Stenzel, K. H., Rubin, A. L., & Zaizov, R. (1983) · Cancer · doi:10.1002/1097-0142(19830101)51:1<9::aid-cncr2820510104>3.0.co;2-4 · Cited by 159
Tsao, D., Morita, A., Bella, A., Luu, P. V., & Kim, Y. S. (1982) · PubMed · Cited by 135
Siavoshian, S., Blottière, H. M., Cherbut, C., & Galmiche, J. P. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6255 · Cited by 103
Effects of differentiation‐inducing agents on maturation of human MCF‐7 breast cancer cells
Guilbaud, N., Gas, N., Dupont, M.-A., & Valette, A. (1990) · Journal of Cellular Physiology · doi:10.1002/jcp.1041450122 · Cited by 101
Derivatives of butyric acid as potential anti‐neoplastic agents
Rephaeli, A., Rabizadeh, E., Aviram, A., Shaklai, M., Ruse, M., & Nudelman, A. (1991) · International Journal of Cancer · doi:10.1002/ijc.2910490113 · Cited by 86
Properties of an Acidic Histone-binding Protein Fraction from Cell Nuclei
Vidali, G., Boffa, L. C., & Allfrey, V. G. (1972) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)44638-3 · Cited by 73
Sodium butyrate induces differentiation in breast cancer cell lines expressing the estrogen receptor
Graham, K., & Buick, R. N. (1988) · Journal of Cellular Physiology · doi:10.1002/jcp.1041360108 · Cited by 64
Histone deacetylase from calf thymus
Inoue, A., & Fujimoto, D. (1970) · Biochimica et Biophysica Acta (BBA) - Enzymology · doi:10.1016/0005-2744(70)90015-x · Cited by 60
Reversal of multidrug resistance by a novel quinoline derivative, MS-209
Sato, W., Fukazawa, N., Nakanishi, O., et al. (1995) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00689444 · Cited by 58
Self-citationPouillart, P., Cerutti, I., Ronco, G., et al. (1991) · International Journal of Cancer · doi:10.1002/ijc.2910490117 · Cited by 41
Ryan, M. P., Borenfreund, E., & Higgins, P. J. (1987) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/79.3.555 · Cited by 26
Higgins, P. J., & Ryan, M. P. (1991) · Biochemical Journal · doi:10.1042/bj2790883 · Cited by 24
Hoessly, M. C., Rossi, R., & Fischkoff, S. A. (1989) · PubMed · Cited by 20
Cited by
Histone deacetylases (HDACs): characterization of the classical HDAC family
RUIJTER, A. J. M. D., GENNIP, A. H. V., CARON, H. N., KEMP, S., & KUILENBURG, A. B. P. V. (2003) · Biochemical Journal · doi:10.1042/bj20021321 · Cited by 3,114
Erasers of Histone Acetylation: The Histone Deacetylase Enzymes
Seto, E., & Yoshida, M. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a018713 · Cited by 1,989
Histone deacetylases and cancer: causes and therapies
Marks, P. A., Rifkind, R. A., Richon, V. M., Breslow, R., Miller, T., & Kelly, W. K. (2001) · Nature reviews. Cancer · doi:10.1038/35106079 · Cited by 1,866
Roth, S. Y., Denu, J. M., & Allis, C. D. (2001) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.70.1.81 · Cited by 1,845
Histone-deacetylase inhibitors: novel drugs for the treatment of cancer
Johnstone, R. W. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd772 · Cited by 1,515
Metadata
- Authors
- Saito, A., Yamashita, T., Mariko, Y., Nosaka, Y., Tsuchiya, K., Ando, T., Suzuki, T., Tsuruo, T., & Nakanishi, O.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1999-04-13
- Volume
- 96
- Issue
- 8
- Pages
- 4592-4597
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2082739830
- Cited by
- 694
- References
- 46
- FWCI
- 9.35
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.